Melbourne-based Invetech has announced a new cell therapy manufacturing platform, which can help deal with conditions such as lung cancer and autoimmune diseases.
The second-generation formulation and fill platform allows for the low-cost, commercial-scale manufacture of cell therapies, such as chimeric antigen receptor T-cell (CAR-T) therapy, which has been utilised for the treatment of leukemia.
Invetech is a manufacturer of commercial-scale equipment for international biotherapeutics companies which produce life-saving therapies.
Visiting Invetech’s headquarters in Melbourne, Minister for Jobs, Innovation and Trade, Martin Pakula, pointed to the world-wide reach of medical manufacturing in Victoria.
“Invetech’s new Formulation and Fill Platform is a great example of Victoria’s ability to produce world-leading medtech and pharma innovations that have global impacts,” said Pakula.
According to the Victorian government, the medical technologies and pharmaceuticals sector in the state employs more than 31,000 people and generates $21 billion in revenue. Investment by the state government has led to $234 million in capital expenditure in the sector.
Invetech is part of the MedTech precinct, a cluster of medical technology manufacturers in Melbourne’s eastern suburbs. Being closely located to other manufacturers was a strength for the company, highlighted David Kneen, vice president cell therapy Invetech.
“Victoria’s flourishing medtech hub is an ideal place to develop our cell therapy manufacturing and diagnostic solutions.”